title: Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease.
abstract: We recently identified macrophage inflammatory protein 1-alpha (MIP-1alpha) as a factor produced by multiple myeloma (MM) cells that may be responsible for the bone destruction in MM (1). To investigate the role of MIP-1alpha in MM bone disease in vivo, the human MM-derived cell line ARH was stably transfected with an antisense construct to MIP-1alpha (AS-ARH) and tested for its capacity to induce MM bone disease in SCID mice. Human MIP-1alpha levels in marrow plasma from AS-ARH mice were markedly decreased compared with controls treated with ARH cells transfected with empty vector (EV-ARH). Mice treated with AS-ARH cells lived longer than controls and, unlike the controls, they showed no radiologically identifiable lytic lesions. Histomorphometric analysis demonstrated that osteoclasts (OCLs) per square millimeter of bone and OCLs per millimeter of bone surface of AS-ARH mice were significantly less than in EV-ARH mice, and the percentage of tumors per total bone area was also significantly decreased. AS-ARH cells demonstrated decreased adherence to marrow stromal cells, due to reduced expression of the alpha(5)beta(1) integrin and diminished homing capacity and survival. These data support an important role for MIP-1alpha in cell homing, survival, and bone destruction in MM.
authors.affiliation: Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio, Texas, USA.
authors.forename: S J
authors.initials: SJ
authors.lastname: Choi
authors.forename: Y
authors.initials: Y
authors.lastname: Oba
authors.forename: Y
authors.initials: Y
authors.lastname: Gazitt
authors.forename: M
authors.initials: M
authors.lastname: Alsina
authors.forename: J
authors.initials: J
authors.lastname: Cruz
authors.forename: J
authors.initials: J
authors.lastname: Anderson
authors.forename: G D
authors.initials: GD
authors.lastname: Roodman
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000032:analysis; D016375:Antisense Elements (Genetics) / Q000627:therapeutic use*; D001847:Bone Diseases / Q000209:etiology / Q000517:prevention & control*; D018821:CD18 Antigens / Q000032:analysis; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D006801:Humans; D039482:Integrin alpha5; D019012:Integrin beta1 / Q000032:analysis; D019402:Macrophage Inflammatory Proteins / Q000037:antagonists & inhibitors / Q000502:physiology*; D051379:Mice; D016513:Mice, SCID; D009101:Multiple Myeloma / Q000150:complications / Q000628:therapy*; D010010:Osteoclasts / Q000502:physiology
chemical_list: D015703:Antigens, CD; D016375:Antisense Elements (Genetics); D018821:CD18 Antigens; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D039482:Integrin alpha5; D019012:Integrin beta1; D019402:Macrophage Inflammatory Proteins